Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1292

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 5
Chunk 1292
---
. This is an application for
a 3-year Phase II trial that is expected to be completed with approximately 100 patients that have Mild Cognitive Impairment. We expect a decision on this grant application in May 2025. There is no guarantee that the application will be approved, and the trial will be put on hold if an approval
is not awarded to the Company. A draft of the final study design is not yet determined but a draft synopsis is described in “Item
1. Business - “ of this Annual Report on Form 10-K.

83

We have recently entered into service agreements in
the areas of Business Development, CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management with
companies that has their main operation in Hong Kong. These agreements are with companies that, we believe, have the knowledge and network
in the South-East Asian market to accelerate steps that is needed to have a product that can have treatment value in the territory. The
agreements are further described in the section “Activities in Asia”.

In March 2025, the Company announced that it had entered
into a partnership with Aquanova AG to develop a series of nutritional products targeting longevity, aging and Healthspan. The first three
products, which will focus on the concept of “Beauty from Within”, are slated to hit the market in the third quarter of 2025
through a Direct-to-Consumer model. The Company will form a wholly-owned subsidiary to focus on the consumer market, and will market its
products on a to-be-developed website targeting the US market, along with social media marketing. Internationally, the Company is focusing
on partners who can market and accelerate sales, with an initial focus on the Asian region.

Financial
Position

For
the fiscal years ended December 31, 2024 and 2023, we generated no revenues from product sales and reported net losses of $2,439,625
and $4,783,689, respectively, and negative cash flow from operating activities of $3,911,004 and $480,953, respectively. As noted in
our financial statements, as of December 31, 2024, we had an accumulated deficit of $26,022,129. There is substantial doubt regarding
our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as
well as our dependence on private equity and financings. See “Risk Factors—We have a history of